Clinical Trial Update: Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR). [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating minimally invasive, sphincter-sparing total mesorectal excision for ultra-low rectal cancer after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Mansoura University | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN